Cryo-Cell International, Inc.

NYSE American:CCEL

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🔍 Research & Consulting

Location

United States

Market Cap

USD 36.66 M

Share Price

USD 4.55

Avg Daily Volume

10,927

Change (1 day)

-2.78%

Change (1 year)

-36.01%

Change (YTD)

-38.60%

Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2025: 11.32%

Cryo-Cell International, Inc. EBITDA Margin is 11.32% for the Trailing 12 Months (TTM) ending May 31, 2025, a -137.64% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2024 was -30.06%, a -259.25% change year over year.
Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2023 was 18.88%, a 9.41% change year over year.
Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2022 was 17.26%, a -32.84% change year over year.
Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2021 was 25.69%, a 13.22% change year over year.